Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • Hodgkin's disease  (3)
  • Multiple myeloma  (2)
  • Data management quality control  (1)
  • 1
    Electronic Resource
    Electronic Resource
    Behandlungsergebnisse mit dem ABVD-Schema bei C-MOPP-resistentem Morbus Hodgkin (1981)
    Springer
    Journal of molecular medicine 59 (1981), S. 267-273 
    Details
    ISSN: 1432-1440
    Keywords: Hodgkin's disease ; MOPP-failures ; ABVD ; Morbus Hodgkin ; MOPP-Resistenz ; ABVD
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Zusammenfassung 22 Patienten wurden mit dem ABVD-Protokoll behandelt. 19 (18 × IV B, 1 × III B) sind auswertbar. Kein Patient mit eingeschränkter, aber 7 von 13 Patienten mit intakter Knochenmarksfunktion erreichten eine Vollremission. Alle vier Patienten mit therapie- und krankheitsfreiem Intervall aber nur von 3 von 13 Patienten ohne freies Intervall erreichten ebenfalls eine Vollremission. Vorbehandlung, Histologie, Dauer der Erkrankung und Lebensalter hatten keinen eindeutigen Einfluß auf die Remissionszahlen. Die Toxizität war insbesondere bei über 50-jährigen Patienten erheblich. Zwei Patienten dieser Altersgruppe brachen die Therapie wegen gastrointestinaler Nebenwirkungen ab und 2 von 8 starben an ABVD-mitverursachten Erkrankungen (1 Leukämie, 1 plötzlicher Herztod). Bei drei Patienten mit hochdosierter Mediastinalbestrahlung war eine Pneumonitis eine der wesentlichen Todesursachen. Nach unseren Ergebnissen ist ABVD ein effektives Chemotherapieprotokoll für einige Subgruppen der „MOPP-Versager“.
    Notes: Summary 22 patients were treated with ABVD, 19 (18 stage IV B 1 stage III B) could be evaluated. No patient with impaired but 7 of 13 patients with intact bone-marrow function achieved a complete remission. A complete remission was also achieved by all 4 patients with a treatment- and disease-free interval but only by 3 of 15 without a free interval. Pretreatment, histology, duration of disease, and age showed no clear prognostic significance with respect to induction of remission. Toxicity was severe especially in patients over 50 years of age. 2 patients discontinued therapy because of gastro-intestinal toxicity. 2 of 8 died of treatment-related causes (1 leukemia, 1 sudden cardiac death). In 3 patients with high-dose mediastinal irradiation a pneumonitis secondary to bleomycin contributed significantly to death. Our results suggest that ABVD is an effective salvageregimen for some subgroups of MOPP-failures.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01478205
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    Analyse prognostischer Faktoren beim Plasmozytom (1984)
    Springer
    Journal of molecular medicine 62 (1984), S. 896-905 
    Details
    ISSN: 1432-1440
    Keywords: Multiple myeloma ; Prognostic factors ; Staging systems
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary For analysis of prognostic factors the clinical course of 109 patients with multiple myeloma was evaluated. Survival curves of immunoglobulin (Ig)G- and IgA-myelomas were identical (Fig. 1) with median survival times of 52 and 42 months, respectively, whereas patients with IgD- and Bence-Jones-myeloma had short survival times (median 3 months). Most important risk factors were anemia, renal insufficiency, and hypercalcemia (Figs. 7 and 8). Median survival time dropped from 52 months (Hb above 100 g/l) to 22 (Hb 85–100 g/l) and 1 month (Hb below 85 g/l). Patients with serum creatinine values below 2 mg/dl lived significantly longer than those with values above. Median survival times were 52 and 1 month, respectively. All seven hypercalcemic patients had a renal insufficiency and were in a very poor condition; their median survival time was 1 month. Analysis of the widely used staging system of Durie and Salmon [16] gave disappointing results. Survival curves of the three A-stages ran close together with median survival times of 58, 51, and 36 months. Only the A-B classification according to renal function (A: creatinine under 2 mg/dl; B: creatinine above 2 mg/dl) proved prognostically relevant.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01727438
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 3
    Electronic Resource
    Electronic Resource
    High-dose chemotherapy and hematopoietic stem cell rescue in patients with relapsed Hodgkin's disease (1993)
    Springer
    Annals of hematology 66 (1993), S. 251-256 
    Details
    ISSN: 1432-0584
    Keywords: Hodgkin's disease ; High-dose therapy ; Bone marrow transplantation
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Fifty-one consecutive patients with Hodgkin's disease (HD) have been treated with high-dose chemotherapy (HDT) and transplantation of autologous bone marrow (BM) (n=44), autologous BM plus peripheral blood stem cells (PBSC) (n=2), PBSC (n=1), syngeneic (n=1), or allogeneic BM (n=3). All patients had received standard salvage chemotherapy prior to HDT and were classified as sensitive (n=33) or resistant (n=17) to this treatment; one patient was in untreated relapse prior to BMT. The preparative regimens for patients receiving autologous BM and/or PBSC consisted of cyclophosphamide, VP 16, and BCNU (CVB) (n=44) or BCNU, etoposide, ara-C, and melphalan (BEAM) (n=3). The patients receiving allogeneic transplants were treated with the CVB regimen (n=2) or busulfan (16 mg/kg body wt.) and cyclophosphamide (200 mg/kg body wt.). With a median follow-up of 12 months, overall survival for 44 patients grafted with autologous BM is 61%±9%, progression-free survival for patients with sensitive disease is 44%±11%; no patient with resistant relapse survived beyond 1 year post transplant. Two of three patients grafted with allogeneic BM still survive 15 and 24 months after BMT with Karnofsky performance scores of 70% and 100%, respectively. The main toxicity encountered with the CVB regimen was interstitial pneumonia (IP), seen in four of 15 patients (27%) receiving ≥600 mg/m2 of BCNU. Three of these patients have died. The results show that HDT followed by hematopoietic stem cell rescue may effectively salvage an important fraction of patients with relapsed HD who respond to standard chemotherapy. The same approach is largely unsuccessful in patients with proven refractoriness to standard chemotherapy. Whether HDT followed by BMT or PBSC support is superior to intensive chemotherapy without stem cell support can be answered only by a prospectively randomized trial.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01738475
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 4
    Electronic Resource
    Electronic Resource
    Transplant activities in Germany in 1998 – a survey facilitated by the National Registry for Hemopoietic Stem Cell Transplantation (2000)
    Springer
    Annals of hematology 79 (2000), S. 437-443 
    Details
    ISSN: 1432-0584
    Keywords: Key words Blood stem cell transplantation ; Data management quality control
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract  To improve the infrastructure of hemopoietic stem-cell transplantations in our country, the German Registry for Hemopoietic Stem-Cell Transplantations (DRST) was established in 1998. The present paper summarizes the current status of the DRST and gives a survey of transplant activities in Germany in 1998 in terms of transplant units, transplant types, transplant frequencies and underlying diseases.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/s002770000194
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 5
    Electronic Resource
    Electronic Resource
    Prognostic factors in COPP-treated patients with Hodgkin's disease (1982)
    Springer
    Annals of hematology 44 (1982), S. 339-348 
    Details
    ISSN: 1432-0584
    Keywords: Hodgkin's disease ; Risk factors ; Staging system ; Chemotherapy
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary In a recently published review of the literature [40] we came to the conclusion that the Ann-Arbor staging classification is of limited prognostic value for chemotherapy of Hodgkin's disease (Table 2). Four risk factors accounted for impaired complete remission rates: stage IVB, lymphocyte depletion or not classifiable histologic type, previous chemotherapy, and older age. Fifty-eight evaluable patients were treated with COPP; 23 reached a complete remission (40%). Disease-free survival was 31%, overall survival 49% after five years [33]. Besides the known risk factors, impaired bone marrow function (leucocyte counts 〈4×109/1, platelet counts 〈100×109/1) at the start of therapy was associated with poor treatment results: none of six patients achieved a complete remission [41]. Eleven of 16 patients with no and 11 of 23 patients with one risk factor achieved a complete remission, as did only one patient with more than one risk factor. Survival rates after 30 months were; 87% with no, 66% with one, 36% with two, and 13% with more than two risk factors. We can conclude from our results that the prognosis of patients undergoing chemotherapy for Hodgkin's disease depends on the number of risk factors.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00319917
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 6
    Electronic Resource
    Electronic Resource
    Plasmapheresis in paraproteinemia (1985)
    Springer
    Annals of hematology 50 (1985), S. 321-330 
    Details
    ISSN: 1432-0584
    Keywords: Plasmapheresis ; Plasma exchange ; Paraproteinemia ; Multiple myeloma ; Therapy
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Indications, results, techniques, laboratory monitoring and complications of therapeutic plasmapheresis in patients with symptomatic paraproteinemia are reviewed. In paraproteinemia associated with severe complications plasmapheresis has been used successfully as an emergency treatment, as a treatment that reduces temporarily the paraprotein level until reduction of resynthesis is reached by cytotoxic therapy, or as a longterm adjuvant therapy in cases of slowly proliferating plasma-cytoma or lymphoma. Plasmapheresis has not been shown to influence the underlying malignant process. Paraprotein-related complications that can be reduced by plasmapheresis are hyperviscosity, hypervolemia, haemorrhagic diathesis, cryoglobulinemic symptoms, rapidly deteriorating renal insufficiency, visual impairment, and neurologic disturbances. Technically, largepored plasma filters have some advantage as compared to centrifugation techniques. Paraprotein-specific complications of therapeutic plasmapheresis are rare. As an ancillary treatment, therapeutic plasmapheresis has expanded the therapeutic tools in the management of paraproteinemia.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00320925
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...